However, because of the spatial and temporal heterogeneity of HER2 expression in breast cancer, this invasive method only detects HER2 expression in a small portion of tumor tissues, resulting in false-negative results and failure to systemically reflect and dynamically monitor HER2 status during the disease course [6, 7]. Here, ERBB2 is linked to breast cancer.